Display Settings:

Format

Send to:

Choose Destination
Clinicoecon Outcomes Res. 2014 Apr 8;6:187-96. doi: 10.2147/CEOR.S44079. eCollection 2014.

Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax(®)) in children.

Author information

  • 1York Health Economics Consortium, York, UK.
  • 2ALK-Abelló A/S, Hørsholm, Denmark.
  • 3Ruhr-Universität Bochum, Bochum, Germany.

Abstract

BACKGROUND:

Grass pollen-induced rhinoconjunctivitis is a common allergic respiratory disorder affecting over 20% of the UK population in terms of quality of life and sleep, work, and school patterns. The SQ-standardized grass allergy immunotherapy tablet (AIT) has been demonstrated as a disease-modifying treatment which gives a sustained effect even after completion of a treatment course. The objective of this study was to provide an economic assessment of whether treatment with the SQ-standardized grass AIT, Grazax(®) (Phleum pratense) in combination with symptomatic medications is preferable to the standard of care using symptomatic medications only. The analysis was performed for children with grass pollen-induced rhinoconjunctivitis, with or without concomitant asthma, in the UK.

METHODS:

The model evaluated the two treatment regimens in a cohort of 1,000 children from a payer's perspective. Treatment was modeled in terms of management of symptoms, impact on resource use, and development of allergic asthma. The analysis modeled the use of SQ-standardized grass AIT and the sustained effects of treatment over a 9-year time horizon (ie, 3 years of treatment, with modeled long-term benefits). Data inputs were drawn from a recent clinical trial, published studies, and databases.

RESULTS:

SQ-standardized grass AIT improves patient outcomes, generating an incremental cost per quality-adjusted life year gained of £12,168. This is below commonly accepted thresholds in the UK.

CONCLUSION:

The resulting incremental cost per QALY falls below commonly accepted willingness to pay thresholds. Therefore, the SQ-standardized grass AIT is a cost-effective option for the treatment of grass pollen-induced rhinoconjunctivitis in the UK pediatric population.

KEYWORDS:

United Kingdom; cost; cost-benefit; cost-effectiveness; infant; quality of life; rhinoconjunctivitis

PMID:
24812522
[PubMed]
PMCID:
PMC4011810
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk